// App-Quantinova.ai

: Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Santosh Gupta

Principal Investigators

  • Susan Halabi

  • Gabor Kemeny

  • Monika Anand

  • David M. Nanus

  • Paraskevi Giannakakou

  • Daniel J. George

  • Simon Gregory

  • Andrew J. Armstrong

Medical Centers

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Duke University Medical Center, Durham, NC

  • Duke University, Durham, NC

  • Sandra and Edward Meyer Cancer Center, New York, NY

  • Weill Cornell Medicine/Meyer Cancer Center, New York, NY

  • Duke University College of Medicine, Durham, NC

  • Duke Cancer Institute, Durham, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02269982

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved